Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Common Equity (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Common Equity for 4 consecutive years, with -$438.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 72.79% to -$438.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$438.2 million, a 72.79% decrease, with the full-year FY2025 number at -$438.2 million, down 72.79% from a year prior.
  • Common Equity was -$438.2 million for Q4 2025 at Phathom Pharmaceuticals, down from -$422.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $38.0 million in Q1 2022 to a low of -$438.2 million in Q4 2025.
  • A 4-year average of -$166.3 million and a median of -$119.3 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 351.43% in 2023, then plummeted 1428.57% in 2024.
  • Phathom Pharmaceuticals' Common Equity stood at -$74.8 million in 2022, then increased by 2.75% to -$72.8 million in 2023, then crashed by 248.52% to -$253.6 million in 2024, then tumbled by 72.79% to -$438.2 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Common Equity are -$438.2 million (Q4 2025), -$422.5 million (Q3 2025), and -$405.8 million (Q2 2025).